Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.
Ontology highlight
ABSTRACT: Acute myeloid leukemia (AML) is a type of blood cancer characterized by the uncontrolled clonal proliferation of myeloid hematopoietic progenitor cells in the bone marrow. The outcome of AML is poor, with five-year overall survival rates of less than 10% for the predominant group of patients older than 65 years. One of the main reasons for this poor outcome is that the majority of AML patients will relapse, even after they have attained complete remission by chemotherapy. Chemotherapy, supplemented with allogeneic hematopoietic stem cell transplantation in patients at high risk of relapse, is still the cornerstone of current AML treatment. Both therapies are, however, associated with significant morbidity and mortality. These observations illustrate the need for more effective and less tox
SUBMITTER: Van Acker HH
PROVIDER: S-EPMC6572115 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA